At Rush University Medical Center, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.

Excellence is just the beginning.


French German Italian Portuguese Russian

Childhood B-Lymphoblastic Leukemia Treatment Study

Clinical Trial Title: 
Risk-stratified randomized phase III testing of blinatumomab (IND# I17467, NSC# 765986) in first relapse of childhood B-lymphoblastic leukemia (B-ALL).
Clinical Trial Protocol ID: 
Clinical Trial Investigator Name: 
Mary Lou Schmidt, MD
Clinical Trial Protocol Description: 

AALL 1331 is a group wide risk-stratified, randomized phase III study to test whether incorporation of blinatumomab into the treatment of patients with childhood B-lymphoblastic leukemia (B-ALL) at first relapse will improve disease free survival. Blinatumomab is being tested in this population based on its demonstrated safety profile and single agent activity (induction of MRD-negative remissions in children with multiple relapsed refractory B-ALL).

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Are between one year of age and 31 years of age at the time of relapse.
  • Have had first relapse of B-ALL. Allowable sites of disease include isolated bone marrow, combined bone marrow and CNS and/or testicular, and isolated CNS and/or testicular.

This is a partial list of elgibility requirements.

Clinical Trial Area: 
Pediatric Cancers and Blood Disorders
Contact Email: 
Contact Phone: 
(312) CANCER-1
Contact Name: 
Rush Cancer Center Clinical Trials Office